ID
40
Cancer Name
Prostate Adenocarcinoma – Extension
Main Grouping
Reproductive
Organ System
Prostate
Cell Origin
Glandular epithelial cells
Pathways Affected
Prostate adenocarcinoma is defined by the androgen receptor (AR) signaling pathway as the foundational oncogenic driver, with PI3K/AKT/mTOR constitutive activation through PTEN loss, TMPRSS2-ERG fusion-driven ETS transcription factor dysregulation, p53 tumor suppressor loss, RB1/cell cycle checkpoint disruption, and NF-kB inflammatory signaling as the primary molecular axes.
The androgen receptor signaling pathway is the dominant driver of prostate adenocarcinoma throughout all disease stages from primary to castration-resistant metastatic disease; testosterone is converted to dihydrotestosterone (DHT) by 5-alpha reductase in prostate cells, and DHT binds the AR ligand-binding domain with high affinity (approximately 5-fold greater than testosterone); DHT-AR complex translocates to the nucleus and activates transcription of androgen response element (ARE)-bearing genes including KLK3 (PSA), TMPRSS2, SLC45A3, CAMKK2, and cell cycle targets; AR signaling drives luminal epithelial cell proliferation, survival, and differentiation; dietary phytoestrogens including genistein and daidzein from soybeans compete with estradiol for estrogen receptor binding and additionally inhibit 5-alpha reductase activity and AR transcriptional activity in prostate cancer cell models; lycopene from tomatoes inhibits AR-mediated gene expression in prostate cancer cell models.
The PI3K/AKT/mTOR pathway is constitutively activated through PTEN loss-of-function in approximately 40 percent of primary prostate cancer and up to 70 percent of mCRPC; PTEN encodes a phosphatase that directly dephosphorylates PIP3 (the PI3K product) to terminate PI3K signaling; PTEN loss releases the PI3K/AKT/mTOR axis from negative regulation driving constitutive AKT phosphorylation and mTORC1-mediated protein synthesis, metabolic reprogramming, and AR cross-activation; curcumin inhibits PI3K/AKT and reduces AR levels in LNCaP (PTEN-null) prostate cancer cells; quercetin inhibits AKT and NF-kB in PTEN-null PC-3 prostate cancer cells. The TMPRSS2-ERG fusion drives ETS transcription factor dysregulation in approximately 40 to 50 percent of prostate cancer by placing the ERG proto-oncogene under androgen-responsive TMPRSS2 promoter control, enabling ERG to act as an aberrant transcriptional activator of genes promoting invasion, proliferation, and epithelial plasticity; ERG expression co-occurs with PTEN loss in a significant fraction of cases creating compounded PI3K/AKT/AR pathway activation. The NF-kB pathway is constitutively activated in androgen-independent and castration-resistant prostate cancer through PI3K/AKT downstream signaling, TNF-alpha/IL-6 cytokine signaling in the prostate tumor microenvironment, and loss of IkB regulators; curcumin suppressed both constitutive (DU145) and inducible (LNCaP) NF-kB activation in prostate cancer cells (PMC3368543). The p53 tumor suppressor pathway is disrupted in approximately 8 to 10 percent of primary prostate cancer and up to 35 percent of mCRPC through TP53 mutations; p53 loss eliminates DNA damage checkpoint function and enables AR splice variant production and lineage plasticity; EGCG activates growth arrest and apoptosis via p53-dependent pathway involving p21 and Bax in prostate cancer cell models (PMC3368543). The RB1/cell cycle checkpoint pathway is disrupted in approximately 13 percent of primary prostate cancer and up to 35 percent of mCRPC through RB1 deletion or inactivation; RB1 loss releases E2F transcription factors driving cell cycle progression and enables neuroendocrine transdifferentiation in advanced disease. The MAPK/ERK pathway is activated downstream of EGFR, FGFR, and RAS signaling in a subset of prostate cancer, contributing to AR-independent proliferation in castration-resistant disease. The Wnt/beta-catenin pathway is activated in a subset of prostate cancer through beta-catenin stabilizing mutations and APC mutations; Wnt/beta-catenin activation directly enhances AR transcriptional activity through AR-beta-catenin interaction. The mTORC1 signaling pathway is activated through PTEN loss and PI3K/AKT pathway constitutive activation in approximately 40 percent of prostate cancer; mTORC1 drives anabolic metabolism, protein synthesis, and AR translation relevant to androgen-driven prostate cancer biology; curcumin and quercetin both inhibit mTORC1 in prostate cancer cell models. The IGF-1 signaling pathway is active in prostate cancer through IGF-1R expression on prostate cancer cells, with IGF-1 stimulating both PI3K/AKT and MAPK/ERK proliferative signaling and directly stimulating AR transcriptional activity; dietary phytochemicals including genistein and EGCG inhibit IGF-1R in prostate cancer models. The mevalonate/cholesterol pathway is highly relevant to prostate adenocarcinoma as the cholesterol precursor for testosterone and DHT biosynthesis, and as a direct source of lipid raft membrane constituents required for AR membrane trafficking; resveratrol and EGCG inhibit cholesterol synthesis-related enzymes in prostate cancer models. The epigenetic/DNA methylation pathway is directly relevant to prostate cancer through GSTP1 promoter hypermethylation (present in greater than 90 percent of prostate cancers), CDH1, and APC silencing; the quercetin-curcumin combination demethylated AR promoter CpG sites and restored AR expression in AR-negative PC-3 and DU145 cells (PMC11842649). The prostaglandin/COX pathway is activated in prostate cancer through COX-2 overexpression driving PGE2 production; EGCG inhibited COX-2 in LNCaP and PC-3 prostate cancer cells (PMC3368543).
Description
Prostate adenocarcinoma is the most common non-skin cancer in men in the United States and the second leading cause of cancer death in American men. An estimated 299,010 new cases of prostate cancer and approximately 35,250 deaths were projected in the United States in 2024. Globally, prostate cancer is the second most commonly diagnosed cancer in men and the fifth leading cause of cancer death in men, with approximately 1,467,000 new cases and 396,800 deaths reported globally in 2022. The 5-year relative survival for all stages combined in the United States is approximately 97 percent; however, for distant stage IV metastatic disease the 5-year survival drops to approximately 34 percent. The primary site of distant metastasis is bone, with approximately 90 percent of metastatic prostate cancer involving the skeletal system, primarily through osteoblastic bone lesions; other common metastatic sites include lymph nodes, lungs, and liver.
Prostate adenocarcinoma is the dominant histological type (greater than 95 percent of prostate cancers). The Gleason grading system scores prostate cancer based on glandular architecture from 1 to 5 (well-differentiated to undifferentiated); the current Grade Group system (1-5) based on Gleason patterns provides more accurate prognostic stratification. The androgen receptor (AR) signaling axis is the foundational driver of prostate adenocarcinoma biology: testosterone and dihydrotestosterone (DHT) bind AR in the cytoplasm, driving AR nuclear translocation and transcriptional activation of genes including KLK3 (PSA), TMPRSS2, and proliferative targets; androgen deprivation therapy (ADT) targeting AR signaling is the primary treatment for locally advanced and metastatic prostate cancer.
The TCGA molecular taxonomy of primary prostate cancer (2015) identified seven molecular subtypes defined by ETS gene fusions and recurrent mutations; the most common subtype is TMPRSS2-ERG gene fusion (40 to 50 percent), which places the ERG proto-oncogene under androgen-responsive TMPRSS2 promoter control; PTEN loss in approximately 40 percent directly activates PI3K/AKT/mTOR; TP53 mutations in approximately 8 to 10 percent in primary disease and 35 percent in mCRPC; SPOP mutations in approximately 11 percent encode the most common point mutation in localized prostate cancer; CDK12 mutations in approximately 7 percent of mCRPC define a hypermutant subset.
Multiple plant phytochemicals have documented activity in prostate cancer cell models. A published review (PMC3368543) documented curcumin suppressing both constitutive (DU145) and inducible (LNCaP) NF-kB activation and potentiating apoptosis; EGCG activating growth arrest and apoptosis via p53-dependent pathway involving p21 and Bax in androgen-sensitive LNCaP and androgen-insensitive PC-3 cells and inhibiting COX-2; quercetin, resveratrol, and genistein all demonstrating documented anti-prostate cancer cell line activities.
Plant-Based Description
Whole-food plant-based dietary patterns provide nutrients and phytochemicals with documented activity relevant to prostate adenocarcinoma through direct prostate cancer cell line anti-proliferative activity in androgen-sensitive LNCaP, androgen-insensitive PC-3 and DU145 cell lines, androgen receptor (AR) transcriptional activity reduction targeting the foundational prostate cancer driver, NF-kB inhibition in both androgen-sensitive and androgen-resistant prostate cancer cells, p53/p21/Bax-mediated apoptosis through EGCG, PI3K/AKT/mTOR suppression targeting PTEN-null constitutive pathway activation, COX-2 inhibition reducing PGE2 production, DNMT inhibition restoring tumor suppressor gene expression, IGF-1 signaling reduction, and epigenetic GSTP1 promoter demethylation. Curcumin reduced AR levels and activity in prostate cancer cells and suppressed both constitutive (DU145) and inducible (LNCaP) NF-kB activation (PMC3368543). EGCG activated p53-dependent growth arrest and apoptosis through p21 and Bax in both LNCaP and PC-3 prostate cancer cells and inhibited COX-2. Quercetin inhibited AKT and NF-kB in PC-3 cells. Genistein from soybeans inhibited 5-alpha reductase, AR activity, and PI3K/AKT. Lycopene from tomatoes inhibited androgen receptor-mediated gene expression and IGF-1 signaling in prostate cancer models. Resveratrol activated p53, inhibited NF-kB, and induced apoptosis in prostate cancer cell models. Sulforaphane from cruciferous vegetables inhibited HDAC activity and DNMT activity and activated Nrf2 in prostate cancer cells, targeting GSTP1 epigenetic silencing present in greater than 90 percent of prostate cancers.
Plant Chemistry Detail
Curcumin from turmeric has the most broadly documented AR-suppression and NF-kB inhibitory evidence across multiple prostate cancer cell lines. A published review (PMC3368543) documented curcumin in prostate cancer cells: suppressing both constitutive NF-kB activation in DU145 (androgen-independent, TP53-mutant) cells and inducible NF-kB activation in LNCaP (androgen-sensitive, PTEN-null) cells — directly targeting the NF-kB pathway constitutively active in advanced and castration-resistant prostate cancer; curcumin reduces AR levels and activity in prostate cancer cells, directly targeting the foundational androgen receptor signaling driver; curcumin inhibits PI3K/AKT in LNCaP (PTEN-null) prostate cancer cells, directly targeting the dominant secondary oncogenic axis activated by PTEN loss in approximately 40 percent of prostate cancer; curcumin potentiates apoptosis in prostate cancer cells through caspase activation and Bcl-2/Bax counter-regulation.
EGCG from green tea has documented p53-dependent anti-prostate cancer activity in both androgen-sensitive and androgen-independent prostate cancer cell lines. A published review (PMC3368543) documented: EGCG activating growth arrest and apoptosis in prostate cancer cells via a p53-dependent pathway involving both p21 (CDK inhibitor) and Bax (pro-apoptotic BCL-2 family); this mechanism was confirmed in androgen-sensitive LNCaP cells (PTEN-null) and androgen-insensitive PC-3 cells (PTEN-null, p53-null), demonstrating activity across androgen-status categories; EGCG inhibited COX-2 in LNCaP and PC-3 cells, reducing prostaglandin E2 production from the constitutively active COX-2 inflammatory pathway in prostate cancer; EGCG also inhibited DNMT activity in prostate cancer cells relevant to GSTP1 promoter hypermethylation present in greater than 90 percent of prostate cancers; EGCG inhibited IGF-1R signaling in prostate cancer models.
Quercetin from onions and kale demonstrated prostate cancer cell death across LNCaP, DU-145, and PC-3 cells through ROS modulation, AKT inhibition in PTEN-mutant DU-145 cells, and NF-kB pathway modulation in PC-3 cells through a direct anti-survival mechanism confirmed in multiple genetically distinct prostate cancer cell lines (PMC6001031). The quercetin-curcumin combination demethylated AR promoter CpG sites in AR-negative PC-3 and DU145 cells, restored AR mRNA and protein levels, and promoted apoptosis via mitochondrial depolarization, confirming that this combination targets both DNMT-mediated epigenetic silencing and the AR signaling axis in castration-resistant prostate cancer cell models (PMC11842649). Genistein from soybeans inhibited 5-alpha reductase activity reducing DHT production, reduced AR transcriptional activity, inhibited IGF-1R/PI3K/AKT, and induced G2/M arrest in prostate cancer cell models. Lycopene from tomatoes reduced androgen receptor-mediated gene expression (PSA reduction) and inhibited IGF-1 signaling in prostate cancer models; lycopene combined with phytoene, phytofluene, and beta-carotene demonstrated inhibitory effects on LNCaP cell growth through AR activity inhibition and electrophile/antioxidant response element system activation. Resveratrol from grapes activated p53, inhibited NF-kB through IkB-alpha stabilization, reduced AR expression, and induced apoptosis through Fas/CD95 death receptor activation in prostate cancer models. Sulforaphane from broccoli and cruciferous vegetables inhibited HDAC activity (targeting the extensive epigenetic silencing of GSTP1, CDH1, and APC in prostate cancer), inhibited DNMT activity, activated Nrf2/ARE antioxidant response in prostate cells, and induced G2/M arrest with apoptosis in prostate cancer cell models. Pomegranate ellagic acid and urolithin A have documented anti-proliferative and AR-inhibitory activity in prostate cancer models. Indole-3-carbinol and DIM from cruciferous vegetables modulate androgen metabolism and inhibit AR signaling.
Nutritional Focus
utritional focus in prostate adenocarcinoma research is led by curcumin from turmeric with documented NF-kB suppression in both constitutive (DU145 androgen-independent) and inducible (LNCaP androgen-sensitive) prostate cancer cells, AR level and activity reduction directly targeting the foundational androgen receptor signaling driver, and PI3K/AKT inhibition in PTEN-null LNCaP cells targeting the dominant secondary oncogenic axis activated by PTEN loss in approximately 40 percent of prostate cancer (PMC3368543); EGCG from green tea activating p53-dependent growth arrest and apoptosis through p21 and Bax in both androgen-sensitive LNCaP and androgen-insensitive PC-3 prostate cancer cells and inhibiting COX-2 and DNMT activity targeting GSTP1 hypermethylation present in greater than 90 percent of prostate cancers (PMC3368543); quercetin from yellow onions inducing cell death across all three genetically distinct prostate cancer cell lines (LNCaP, DU-145, PC-3) through ROS modulation, AKT inhibition, and NF-kB modulation (PMC6001031); quercetin-curcumin combination restoring AR expression through DNMT inhibition and CpG demethylation in AR-negative PC-3 and DU145 cells and inducing mitochondrial apoptosis (PMC11842649) — targeting both epigenetic silencing and androgen resistance simultaneously; genistein from soybeans inhibiting 5-alpha reductase reducing DHT production, reducing AR transcriptional activity, and inhibiting IGF-1R/PI3K/AKT in prostate cancer models; lycopene from tomatoes reducing AR-mediated gene expression (PSA) and IGF-1 signaling in prostate cancer models; resveratrol activating p53, inhibiting NF-kB, and inducing Fas/CD95 apoptosis in prostate cancer cell models; sulforaphane from cruciferous vegetables inhibiting HDAC and DNMT targeting GSTP1 silencing in greater than 90 percent of prostate cancers and activating Nrf2/ARE; folate from leafy greens and legumes providing one-carbon units for SAM-cycle methionine chemistry relevant to GSTP1 and APC promoter methylation in prostate cancer; and selenium from Brazil nuts and whole grains supporting glutathione peroxidase activity in prostate epithelial antioxidant defense.
Research Notes
Prostate cancer epidemiology: approximately 299,010 new US cases and 35,250 deaths projected 2024; most common non-skin cancer in US men; 2nd leading cause of cancer death in American men; approximately 1,467,000 new cases globally 2022; 5-year survival all stages approximately 97%; distant metastatic approximately 34%; primary metastatic site bone (approximately 90% of metastatic cases). TCGA molecular taxonomy primary prostate cancer (2015): 7 subtypes: ERG fusions ~46%; ETV1 fusions ~8%; ETV4 fusions ~4%; FLI1 fusions ~1%; SPOP mutations ~11%; FOXA1 mutations ~3%; IDH1 mutations ~1%. PTEN loss ~40% primary, ~70% mCRPC; TP53 mutations ~8-10% primary, ~35% mCRPC; RB1 deletion ~13% primary, ~35% mCRPC; BRCA2 mutations ~5% mCRPC; GSTP1 hypermethylation greater than 90% of prostate cancers.
Curcumin in prostate cancer (PMC3368543): constitutive NF-kB suppression in DU145; inducible NF-kB suppression in LNCaP; AR level/activity reduction; PI3K/AKT inhibition in PTEN-null LNCaP; apoptosis potentiation. EGCG in prostate cancer (PMC3368543): p53-dependent growth arrest/apoptosis p21 and Bax in LNCaP and PC-3; COX-2 inhibition in LNCaP and PC-3; DNMT inhibition. Quercetin in prostate cancer (PMC6001031): LNCaP/DU-145/PC-3 cell death via ROS, AKT, NF-kB modulation. Quercetin-curcumin DNMT inhibition AR restoration in PC-3 and DU145 (PMC11842649).
Notes Visibility
show
Key Foods
Tomato,Broccoli,Kale,Spinach,Brussels Sprouts,Cauliflower,Garlic,Yellow Onion,Carrot,Beetroot,Asparagus,Pomegranate,Blueberry,Raspberry,Grape,Strawberry,Orange,Lemon,Soybeans,Edamame,Green Lentils,Black Beans,Chickpeas,Brown Rice,Quinoa,Oats,Wild Rice,Rye Berries,Sorghum,Walnut,Almond,Brazil Nut,Pumpkin Seeds,Flaxseed,Chia Seeds,Sesame Seeds,Hemp Seeds,Shiitake,Maitake,Cremini,Portobello,Lions Mane,Turmeric,Green Tea,Ginger,Black Pepper,Garlic Powder,Parsley,Rosemary,Oregano, Leek,Avocado,Artichoke,Radish,Tangerine, Red Onion
Linked Nutrients
vitamin-c,vitamin-e,vitamin-d3,vitamin-b9,vitamin-b6,vitamin-a,selenium,zinc,magnesium,calcium,potassium,iron,curcumin,egcg,quercetin,genistein,lycopene,resveratrol,sulforaphane,ellagic-acid,beta-carotene,anthocyanins,beta-glucans,dietary-fiber,plant-ala-omega3
